🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Eli Lilly patient assistance programs — looking for input Page 6

Eli Lilly patient assistance programs — looking for input

pam_stl Tue, Nov 11, 2025 at 2:34 PM 27 replies 1,587 viewsPage 6 of 6
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jan 1, 2026 at 9:26 AM#26

Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Last edited: Jan 1, 2026 at 3:26 PM
39 14kim_atl_prep, sarah_TO, wendy_avl and 36 others
Reply Quote Save Share Report
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Jan 8, 2026 at 12:48 AM#27
Dr.CardioMD said:
The mechanism and the magnitude are separate questions.

This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.

38 13oliver_london, tane_welly, Dr.PathRoch and 35 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Jan 14, 2026 at 4:14 PM#28
Dr.CardioMD said:
The mechanism and the magnitude are separate questions.

Coming at Dr.CardioMD’s question from a different direction. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

37 12tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 34 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Jan 21, 2026 at 7:44 AM#29

The figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Jan 21, 2026 at 8:44 AM
36 11VendorMark, COA_Karl, MikeFit_NJ and 33 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Jan 27, 2026 at 11:18 PM#30

OP back with an update, since a thread like this is useless without one.

Follow-up — getting the denial reason in writing was the step that mattered. It named the criterion, and the criterion was a document I already had.

Last edited: Jan 28, 2026 at 4:18 AM
14 14RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 11 others
Reply Quote Save Share Report
1456

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register